- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02973386
Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients
April 9, 2022 updated by: Zhao Chong, Sun Yat-sen University
Randomized Trial of Concurrent Cisplatin Chemoradiotherapy Plus Capecitabine Adjuvant Chemotherapy vs Concurrent Cisplatin Chemoradiotherapy Alone for Patients With Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis
This is a randomized,controlled,prospective phase III clinical trial.
The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis.Exploring an Individualized comprehensive treatment plan which is reasonable,effective,low toxicity and fitting with Modern radiotherapy techniques for Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis.
Study Overview
Status
Recruiting
Study Type
Interventional
Enrollment (Anticipated)
278
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: wu haijun
- Phone Number: +86-18819200847
- Email: wuhj@sysucc.org.cn
Study Contact Backup
- Name: miao jingjing
- Phone Number: +86-13631355201
- Email: miaojj@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Cancer Center, Sun Yat-sen University
-
Contact:
- Zhao chong, M.D
- Phone Number: +86-13902206160
- Email: zhaochong@sysucc.org.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)
- Clinical stage III~IVb(UICC/AJCC 7th)
- No distant metastasis
- Karnofsky Performance Status Scale≥70
- WBC count ≥ 4×109/L, neutrophil differential count≥ 1.5×109/L, Hemoglobin ≥ 90g/L, platelet count ≥ 100×109/L
- ALT or AST ≤2.5×ULN,bilirubin ≤2.5×ULN, Serum creatinine ≤1.5×ULN or Serum creatinine clearance≥60ml/min
- Sign the informed consent.
Exclusion Criteria:
- Angle of sexual squamous cell carcinomas and basal cell layout, squamous cell carcinomas
- Younger than 18 years old or older than 70 years old
- Are receiving other drugs treanment
- kidney disease
- Have suffered from other tumor or now suffering from other tumor
- Have recieved chemotherapy or radiotherapy
- Pregnancy or lactation
- unstable heart disease need timely treatment
- Severe cerebrovascular disease/canker/psychosis/uncontrolled diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Concurrent chemoradiation + adjuvant chemotherapy
IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
|
Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
|
Active Comparator: Concurrent chemoradiation
IMRT combine with cisplatin concurrent chemotherapy
|
Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant metastasis-free survival
Time Frame: Five year
|
Defined as the time from date of recruitment to documented distant metastasis or death from any cause.
|
Five year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Failure-free survival
Time Frame: Five year
|
Defined as the time from date of recruitment to documented relapse or death from any cause.
|
Five year
|
Locoregional relapse-free survival
Time Frame: Five year
|
Defined as the time from date of recruitment to documented locoregional relapse or death from any cause.
|
Five year
|
Overall survival
Time Frame: Five year
|
Defined as the time from date of recruitment to death from any cause.
|
Five year
|
Acute toxicity
Time Frame: three months after corresponding treatment
|
Acute toxicities were graded using the Common Toxicity Criteria for Adverse Events version 4.0 (CTCAE v4.0) for chemotherapy-specific toxicities, and the Radiation Therapy Oncology Group (RTOG) radiation morbidity scoring criteria for radiotherapy-specific toxicities.
|
three months after corresponding treatment
|
Late toxicity
Time Frame: Five year
|
Late toxicities were assessed annually using the RTOG radiation morbidity scoring criteria.
|
Five year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
December 1, 2025
Study Registration Dates
First Submitted
November 22, 2016
First Submitted That Met QC Criteria
November 22, 2016
First Posted (Estimate)
November 25, 2016
Study Record Updates
Last Update Posted (Actual)
April 15, 2022
Last Update Submitted That Met QC Criteria
April 9, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Carcinoma
- Nasopharyngeal Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Cisplatin
- Capecitabine
Other Study ID Numbers
- CCRT-AC-HRDM-NPC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Local Advanced High Risk Nasopharyngeal Carcinoma
-
Zhao ChongCancer Institute and Hospital, Chinese Academy of Medical Sciences; Jiangxi... and other collaboratorsCompletedLocal Advanced High Risk Nasopharyngeal CarcinomaChina
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer
-
West China HospitalRecruitingChemoradiotherapy | Total Neoadjuvant Treatment | Local Advanced Rectal Cancer | High Risk FactorsChina
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownLOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNTFrance
-
Guiyang Medical UniversityUnknownAdvanced Nasopharyngeal CarcinomaChina
-
Chinese University of Hong KongCompletedAdvanced Nasopharyngeal CarcinomaHong Kong
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Nasopharyngeal CarcinomaChina
-
Zhejiang Cancer HospitalRecruitingAdvanced Nasopharyngeal CarcinomaChina
-
Zhejiang Cancer HospitalZhejiang Provincial People's Hospital; The Central Hospital of Lishui City; First... and other collaboratorsRecruitingLocally Advanced Nasopharyngeal CarcinomaChina
Clinical Trials on IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
-
Zhao ChongCancer Institute and Hospital, Chinese Academy of Medical Sciences; Jiangxi... and other collaboratorsCompletedLocal Advanced High Risk Nasopharyngeal CarcinomaChina
-
Sun Yat-sen UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Fifth Affiliated Hospital... and other collaboratorsNot yet recruiting
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Fujian Cancer HospitalNot yet recruitingNasopharyngeal CarcinomaChina
-
Air Force Military Medical University, ChinaUnknown
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingGastric or Esophagogastric Junction AdenocarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaboratorsRecruitingNasopharyngeal Carcinoma | De-escalation TherapyChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaboratorsRecruitingNasopharyngeal CarcinomaChina
-
Chaosu HuZhejiang Cancer Hospital; Fujian Cancer Hospital; Affiliated Hospital of Jiangnan... and other collaboratorsRecruitingNasopharyngeal CarcinomaChina
-
Chongqing University Cancer HospitalRecruitingHead and Neck Squamous Cell CarcinomaChina